Studies of the synthesis of all stereoisomers of MG-132 proteasome inhibitors in the tumor targeting approach

Journal of Medicinal Chemistry

Volumn 53, Issue 4, 2010, Pages 1509-1518

  Mroczkiewicz, Michal ^a   Winkler, Katarzyna ^a,b   Nowis, Dominika ^c   Placha, Grzegorz ^d   Golab, Jakub ^c   Ostaszewski, Ryszard ^b  

^a WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

^b INSTITUTE OF ORGANIC CHEMISTRY   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

2 FORMAMIDO 4 METHYLPENTYL ACETATE; 2 ISOCYANO 4 METHYLPENTYL ACETATE; ALDEHYDE; AMINO 4 METHYLPENTAN 1 OL LEUCINOL; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CHYMOTRYPSIN; ISOCYANO 4 METHYLPENTYL ACETATE; N [1 (HYDROXYMETHYL) 3 METHYLBUTYL]FORMAMIDE; TRIPEPTIDE; TRYPSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHIRALITY; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENANTIOMER; HYDROLYSIS; MOUSE; NONHUMAN; STEREOISOMERISM;

ANTINEOPLASTIC AGENTS; CHYMOTRYPSIN; ENDOPEPTIDASES; ERYTHROCYTES; HUMANS; HYDROLYSIS; LEUPEPTINS; NITRILES; PROTEASOME ENDOPEPTIDASE COMPLEX; STEREOISOMERISM; TRYPSIN;

EID: 77649210502     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901619n     Document Type: Article

References (40)

1. Nunami, K.-i.; Yamada, M.; Shimizu, R. Design, of novel tripeptides with macrophage migration-enhancing activity. Bioorg, Med, Chem. Lett 1998, 8, 2517-2520.
2. Dragovich, P. S.; Zhou, R.; Skalitzky, D. J.; Fuhrman, S. A.; Patick, A. K.; Ford, C. E.; James, W.; Meador, I.; Worland, S. T. Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. Part 1: Optimization of tripeptides incorporating N-terminal amides. Bioorz. Med. Chem., 1999, 7, 589-598.
3. Amssoms, K.; Oya, S. L.; Augustyns, K.; Yamani, A.; Lambeir, A.-M.; BaI, G.; Veken, P. V. d.; Fairlamb, A. H.; Haemers, A. Glutathione-like tripeptides as inhibitors of glutathionylspermidine synthetase. Part 2: Substitution of the glycine part. Bioorg. Med, Chem, Lett. 2002, 12, 2703-2705. (Pubitemid 35247622)
4. Suto, M. J.; Sullivan, R. W.; Ransone, L. J. Peptide inhibitors of IKB protease: modification of the C-termini of Z-LLF-CHO. Bioorg, Med, Chem, Lett. 1996, 6, 2925-2930.
5. Webber, S. E.; Okano, K.; Little, T. L.; Reich, S. H.; Xin, Y.; Fuhrman, S. A.; Love, D. A. M. R. A.; Hendrickson, T. F.; Patick, A. K.; James, W.; Meador, I.; Ferre, R. A.; Brown, E. L.; Ford, C. E.; Binford, S. L.; Worland, S. T. Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of Pl glutamine isosteric replacements. J. Med. Chem. 1998, 41, 2786-2805. (Pubitemid 28350345)
6. Iqbal, M.; Messina, P. A.; Freed, B.; Das, M.; Chatterjee, S.; Tripathy, R.; Tao, M.; Josef, J. A.; Dembofsky. B.; Dunn, D.: Griffith, E.; Siman, R.; Senadhi, S. E.; Biazzo, W.; BozyczkoCoyne, D.; Meyer, S. L.; Ator, M. A.; Bihovsky, R. Subsite requirements for peptide aldehyde inhibitors of human calpain I. Bioorz. Med. Chem. Lett 1997, 7, 539-544.
7. Braun, H. A.; Umbreen, S.; Groll, M.; Kuckelkorn, U.; Mlynarczuk, I.; Wigand, M. E.; Drung, I.; Kloetzel, R.-M.; Schmidt, B. Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines. J. Biol. Chem. 2005, 280, 28394-28411. (Pubitemid 41105738)
8. Momose, I.; Umezawa, Y.; Hirosawa, S.; Iinuma, H.; Ikeda, D. Structure-based design of derivatives of tyropeptin A as the potent and selective inhibitors of mammalian 20S proteasome. Bioorg. Med, Chem, Lett. 2005, 15, 1867-1871. (Pubitemid 40380749)
9. Adams, J.; Palombella, V. J.; Sausville, E. A.; Johnson, J.; Destree, A.; Lazarus, D. D.; Maas, J.; Pien, C. S.; Prakash, S.; Eliott, P. J. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999, 59, 2615-2622.
10. Wang, J.; Maldonado, M. A. The ubiquitin-proteasome sysytem and its role in inflammatory and autoimmune diseases. Cell. Mol. Immunol. 2006, 3, 255-261.
11. Mani, A.; Gelmann, E. P. The ubiquitin-proteasome pathway and its role in cancer. J. Clin. 2005, 23, 4776-4789. (Pubitemid 46224082)
12. Ciechanover, A.; Brundin, P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003, 40, 427-446. (Pubitemid 37244106)
13. Herrmann, J.; Ciechanover, A.; Lerman, L. O.; Lerman, A. The ubiquitin-proteasome system, in cardiovascular diseases: a hypothesis extended. Cardiovasc. Res. 2004, 61, 11-21. (Pubitemid 38056676)
14. Groll, M.; Gotz, M.; Kaiser, M.; Weyher, E.; Moroder, L. TMC95-based inhibitor design provides evidence for the catalytic versatility of the proteasome. Chem. Biol. 2006, 13, 607-614. (Pubitemid 43912453)
15. Adams, J.; Behnke, M.; Chen, S.; Cruickshank, A. A.; Dick, L. R.; Grenier, L.; Klunder, J. M.; Ma, Y.-T.; Plamondon, L.; Stein, R. L. Potent and selective inhibitors of proteasome: dipeptydyl boronic acids. Bioorg. Med. Chem. Lett. 1998, 8, 333-338.
16. Elofsson, M.; Splittgerber, U.; Myung, J.; Mohan, R.; Crews, C. M. Towards subunit-specific proteasome inhibitors: synthesis and evaluation, of peptide α,β- epoxyketones. Chem. Biol. 1999, 6, 811822.
17. Basse, N.; Piguel, S.; Papapostolou, D.; Ferrier-Berthelot, A.; Richy, N.; Pagano, M.; Satnou, P.; Sobczak-Thepot, J.; Vidal, M. R.-R. J. Linear TMC-95-based proteasome inhibitors. J. Med. Chem. 2007, 50, 2842-2850.
18. Adams, J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5, 417-421. (Pubitemid 38610244)
19. Yan, X.-B.; Yang, D.-S.; Gao, X.; Feng, J.; Shi, Z.-L.; Ye, Z. Caspase-8 dependent osteosarcoma cell apoptosis induced by proteasome inhibitor MG132. Cell Biol. Int. 2007, 31,1136. (Pubitemid 47030977)
20. Domingo-Domenech, J.; Pippa, R.; Tapia, M.; Gascon, P.; Bachs, O.; Bosh, M. Inactivation of NF-kB by proteasome inhibition, contributes to increased, apoptosis induced, by histone deacetylase inhibitors in human breast cancer cell. Breast Cancer Res. Treat. 2008, 112, 53-62.
21. Pajonk, F.; Ophoven, A. v.; Weissenberger, C.; McBride, W. H. The proteasome inhibitor MG-132 sensitizes PC-3 protease cancer cells to ionizing radiation by a DNA-PK-dependent mechanism. BMC Cancer 2005, 5, 76.
22. Holecek, M.; Muthny, T.; Kovarik, M.; Sispera, L. Proteasome inhibitor MG-.132 enhances whole-body protein, in rat. Biochem. Biophys. Res. Commun. 2006, 345, 38-42.
23. Yang, L.;Wang, S.;Lim, G.; Sung, B.; Zeng, Q.;Mao, J. Inhibition of the ubiquitin-proteasome prevents glutamate transporter degradation and morphine tolerance. Pain 2008, 140, 472-478.
24. Stein, R. L.; Ma, Y.-T.; Brand, S. Inhibitors of the 26S Proteolytic Complex and the 20S Proteasome Contained. Therein. U.S. Patent 5693617, 1997.
25. O'Donnell, M. J.; Drew, M. D.; Pottorf, R. S.; Scott, W. L. UPS on. Weinreb resin: a facile solid-phase route to aldehyde and ketone derivatives of "unnatural" amino acids and peptides. J. Comb. Chem. 2002, 2, 172-181.
26. Leban, J.; Busse, M.; Krauss, B.; Rath, S.; Baumgartner, R.; Seifer, M. H. J. Proteasome inhibition bypeptide-semicarbazones. Bioorg, Med, Chem. 2008, 16, 4579-4588.
27. Bajusz, S.; Fauszt, I.; Nemeth, K.; Barabas, E.; Juhasz, A.; Patthy, M. Peptidyl β-homo aspartals: specific inhibitors ofinterleukin-1β converting enzyme and its homologues (caspases). Bioorg, Med, Chem, Lett. 1998, 8, 1477-1482. (Pubitemid 28281408)
28. Fehrentz, J. A.; Pans, M.; Heitz, A.; Velek, J.; Wintermtz, F.; Matinez, J. Solid phase synthesis of C-terminal peptide aldehydes. J. Org. Chem. 1997, 62, 6792-6796. (Pubitemid 127494613)
29. Szymaŕski, W.; Zwolínska, M.; Ostaszewski, R. Studies on the application of the Passerini reaction and enzymatic procedures to the synthesis of tripeptide mimetics. Tetrahedron 2007, 63, 76A77653. (Pubitemid 46962647)
30. Vercillo, O. E.; Andrade, C. K. Z.; Wessjohann, L. A. Design and synthesis of cyclic RGD pentapeptoids by consecutive Ugi reactions. Org. Lett. 2008, 10, 205-208.
31. Waki, M.; Meienhofer, J. Peptide synthesis using four-component condensation. (Ugi reaction); J. Am. Chem. Sac. 1977, 99, 60756082.
32. Zhu, J.; Wu, X.; Danishefsky, S. J. On the preparation of enantiomerically pure isonitriles from, amino ester and peptides. Tetrahedron Lett. 2009, 50, 577-579.
33. Berlozecki, S.; Szymański, W.; Ostaszewski, R. α-Amino acids as acid components in the Passerini reaction: influence of N-protection on the yield, and stereoselectivity. Tetrahedron 2008, 64, 9780.
34. Bayer, T.; Riemer, C.; Kessler, H. A new strategy for the synthesis of cyclopeptides containing diaminoglutaric acid. J. Peat Sci. 2001, 7, 250-261. (Pubitemid 32586584)
35. Mroczkiewicz M.; Ostaszewski, R. A new and general method for the synthesis of tripeptide aldehydes based on the multi-component Ugi reaction. Tetrahedron 2009, 65, 4025-4034.
36. Owens, T. D.; Araldi,G.-L.; Nutt, R. F.; Semple, J. E. Concise total synthesis of the prolyl endopeptidase inhibitor eurystatin A via a novel Passerini reaction-deprotection-acyl migration strategy. Tetrahedron Lett 2001, 42, 6271-6274.
37. Szymaŕiski, W.; Ostaszewski, R. Chemoenzymatic synthesis of enantiomerically enriched α-hydroxyamides. J. Mol, Catal. B: Enzym 2007, 47, 125-128. (Pubitemid 47031674)
38. Koszelewski, D.; Redzej, A.; Ostaszewski, R. The study on efficient hydrolases immobilisation for the kinetic resolution of α-acetoxyamides. J. Mol, Catal. B: Enzym. 2007, 47, 51-57. (Pubitemid 46819153)
39. Rodgers, K. J.; Dean, R. T. Assessment of proteasome activity in cell lysates and tissue homogenates using peptide substrates. Int. J. Biochem. Cell Biol. 2003, 35, 716-727.
40. 4-LiCl. Tetreduction Lett. 1998, 39, 917-918.